Uveitis

• Alternative Names

  Iritis; Pars planitis; Choroiditis; Chorioretinitis; Anterior uveitis; Posterior uveitis

• Causes, incidence, and risk factors

  Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. However, in many cases the cause is unknown.

  The most common form of uveitis is anterior uveitis, which involves inflammation in the front part of the eye. It is often called iritis because it is usually only effects the iris, the colored part of the eye. The inflammation may be associated with autoimmune diseases, but most cases occur in healthy people. The disorder may affect only one eye. It is most common in young and middle-aged people.

  Posterior uveitis affects the back part of the uvea, and involves primarily the choroid, a layer of blood vessels and connective tissue in the middle part of the eye. This type of uveitis is called choroiditis. If the retina is also involved it is called chorioretinitis. You may develop this condition if you have had a body-wide (systemic) infection or if you have an autoimmune disease.

  Another form of uveitis is pars planitis. This inflammation affects the narrow area between the colored part of the eye (iris) and the choroid. Pars planitis usually occurs in young men and is generally not associated with any other disease. However, some evidence suggests it may be linked to Crohn's disease and possibly multiple sclerosis.

  Uveitis can be associated with any of the following:

  • AIDS
  • Ankylosing spondylitis
  • Behcet syndrome
  • CMV retinitis
  • Herpes zoster infection
  • Histoplasmosis
  • Injury
  • Kawasaki disease
  • Psoriasis
  • Reactive arthritis
  • Rheumatoid arthritis
  • Sarcoidosis
  • Syphilis
  • Toxoplasmosis
  • Tuberculosis
  • Ulcerative colitis
• Symptoms

  Uveitis can affect one or both eyes. Symptoms may develop rapidly and can include:

  • Blurred vision
  • Dark, floating spots in the vision
  • Eye pain
  • Redness of the eye
  • Sensitivity to light
• Signs and tests

  A complete medical history and eye examination should be performed. Laboratory tests may be done to rule out infection or an autoimmune disorder.

  Persons over age 25 with pars planitis should have an MRI of their brain and spine to rule out multiple sclerosis.

• Treatment

  Iritis is usually mild. Treatment may involve:

  • Dark glasses
  • Eye drops that dilate the pupil to relieve pain
  • Steroid eye drops or ointment

  Pars planitis is often treated with steroid eye drops. Other medicines, including steroids taken by mouth, may be prescribed to help suppress the immune system.

  Choroiditis treatment depends on the underlying cause. Additional specialists in infectious disease or autoimmunity may be needed for such diseases as syphilis, tuberculosis, AIDS, sarcoidosis, or Behcet's syndrome.

  If the uveitis is caused by a body-wide infection, treatment may involve antibiotics and powerful anti-inflammatory medicines called corticosteroids. See autoimmune disorders for information on treating such diseases.

• Expectations (prognosis)

  With proper treatment, most attacks of anterior uveitis go away in a few days to weeks. However, relapses are common.

  Inflammation related to posterior uveitis may last from months to years and may cause permanent vision damage, even with treatment.

• Complications
  • Cataracts
  • Fluid within the retina
  • Glaucoma
  • Retinal detachment
  • Vision loss
• Calling your health care provider

  Call for an appointment with your health care provider if you have symptoms of uveitis. Eye pain or reduced vision are urgent symptoms that require prompt medical attention.

• Prevention

  Treatment of an underlying disorder may help to prevent uveitis in persons with a body-wide (systemic) infection or disease.

• References

  Olitsky SE, Hug D, Smith LP. Disorders of the Uveal Tract. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap.628.

Review Date: 7/28/2008

Reviewed By: Manju Subramanian, MD, Assistant Professor in Ophthalmology, Vitreoretinal Disease and Surgery, Boston University Eye Associates, Boston, MA. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.